{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-24-000041","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.646746+00:00","generated_at":"2026-05-31T15:23:36.120965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M","bullets":["Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).","Adjusted gross margin from continuing ops 62% (up from 37% YoY).","Adjusted net loss narrowed to $2.7M, an improvement of 93% YoY.","GAAP net loss $29.2M including $13M one-time litigation charge.","Raises FY2024 revenue guidance to $255-265M; reiterates path to profitability in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-24-000041","json":"https://secwatch.observer/filing/0001818331-24-000041.json","markdown":"https://secwatch.observer/filing/0001818331-24-000041.md","text":"https://secwatch.observer/filing/0001818331-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000041/0001818331-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000041/wgs-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:23:36.120965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}